Trial Profile
Biomarker-driven study of BNC 105 in combination with everolimus in patients with renal cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2015
Price :
$35
*
At a glance
- Drugs BNC 105 (Primary) ; Everolimus
- Indications Renal cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Bionomics
- 03 Mar 2015 New trial record
- 27 Feb 2015 Based on biomarker data from the DisrupTOR-1 trial, Bionomics is planning this trial in patients selected on baseline interleukin-8 and ferritin levels, according to a media release.